<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00045188</url>
  </required_header>
  <id_info>
    <org_study_id>NCI-2012-02491</org_study_id>
    <secondary_id>IDO1-691</secondary_id>
    <secondary_id>N01CM17003</secondary_id>
    <secondary_id>CDR0000256915</secondary_id>
    <nct_id>NCT00045188</nct_id>
  </id_info>
  <brief_title>Imatinib Mesylate in Treating Patients With Metastatic Breast Cancer</brief_title>
  <official_title>Phase II Trial of STI571 in Metastatic Breast Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Cancer Institute (NCI)</source>
  <brief_summary>
    <textblock>
      Phase II trial to study the effectiveness of imatinib mesylate in treating patients who have&#xD;
      metastatic breast cancer. Imatinib mesylate may stop the growth of cancer by blocking the&#xD;
      enzymes necessary for tumor cell growth&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      PRIMARY OBJECTIVES:&#xD;
&#xD;
      I. To determine the efficacy of STI571 in metastatic breast cancer (MBC) that demonstrates&#xD;
      expression of CD117 (c-kit) and/ or PDGFR.&#xD;
&#xD;
      SECONDARY OBJECTIVES:&#xD;
&#xD;
      I. To determine the clinical activity of STI571 in MBC with expression of CD117 (ckit) and/&#xD;
      or PDGFR by evaluating progression-free survival (PFS).&#xD;
&#xD;
      II. To determine the toxicity profile and tolerability of STI571 in patients with MBC.&#xD;
&#xD;
      III. To define serum, tissue and imaging surrogate endpoints of activity of STI571 in MBC.&#xD;
&#xD;
      OUTLINE:&#xD;
&#xD;
      Patients receive oral imatinib mesylate twice daily. Treatment continues for at least 8 weeks&#xD;
      in the absence of disease progression or unacceptable toxicity.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>August 2002</start_date>
  <primary_completion_date type="Actual">July 2004</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Objective tumor response (CR + PR), as determined by the RECIST criteria</measure>
    <time_frame>Up to 2 years</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Incidence of adverse events</measure>
    <time_frame>Up to 2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to progression</measure>
    <time_frame>Up to 2 years</time_frame>
    <description>Reported using the Kaplan-Meier method with 95% confidence intervals indicated.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
    <time_frame>Up to 2 years</time_frame>
    <description>Reported using the Kaplan-Meier method with 95% confidence intervals indicated.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">35</enrollment>
  <condition>Male Breast Cancer</condition>
  <condition>Recurrent Breast Cancer</condition>
  <condition>Stage IV Breast Cancer</condition>
  <arm_group>
    <arm_group_label>Treatment (imatinib mesylate)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receive oral imatinib mesylate twice daily. Treatment continues for at least 8 weeks in the absence of disease progression or unacceptable toxicity.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>imatinib mesylate</intervention_name>
    <description>Given PO</description>
    <arm_group_label>Treatment (imatinib mesylate)</arm_group_label>
    <other_name>CGP 57148</other_name>
    <other_name>Gleevec</other_name>
    <other_name>Glivec</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>laboratory biomarker analysis</intervention_name>
    <description>Optional correlative studies</description>
    <arm_group_label>Treatment (imatinib mesylate)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Histologically or cytologically confirmed metastatic breast cancer&#xD;
&#xD;
          -  Documented expression of CD117 (c-kit) or platelet-derived growth factor receptor&#xD;
&#xD;
               -  Adequate tumor tissue from either the primary tumor and/or metastatic disease&#xD;
                  available for evaluation&#xD;
&#xD;
          -  Must have received prior chemotherapy with an anthracycline (doxorubicin or&#xD;
             epirubicin) and/or taxane (paclitaxel or docetaxel) as adjuvant or for advanced&#xD;
             disease&#xD;
&#xD;
          -  At least 1 unidimensionally measurable lesion&#xD;
&#xD;
               -  At least 20 mm by conventional techniques OR at least 10 mm by spiral CT scan&#xD;
&#xD;
               -  Bone disease may not be only source of measurable disease&#xD;
&#xD;
               -  Pleural or peritoneal ascites are not considered measurable disease&#xD;
&#xD;
          -  No known brain metastases&#xD;
&#xD;
          -  Hormone receptor status:&#xD;
&#xD;
               -  Not specified&#xD;
&#xD;
          -  Female or male&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
          -  Performance status - ECOG 0-2&#xD;
&#xD;
          -  Performance status - Karnofsky 60-100%&#xD;
&#xD;
          -  More than 12 weeks&#xD;
&#xD;
          -  Absolute neutrophil count at least 1,500/mm^3&#xD;
&#xD;
          -  WBC at least 3,000/mm^3&#xD;
&#xD;
          -  Platelet count at least 100,000/mm^3&#xD;
&#xD;
          -  Bilirubin normal&#xD;
&#xD;
          -  AST or ALT no greater than 2.5 times upper limit of normal&#xD;
&#xD;
          -  Creatinine normal&#xD;
&#xD;
          -  Creatinine clearance at least 60 mL/min&#xD;
&#xD;
          -  No symptomatic congestive heart failure&#xD;
&#xD;
          -  No unstable angina pectoris&#xD;
&#xD;
          -  No cardiac arrhythmia&#xD;
&#xD;
          -  No other uncontrolled concurrent illness&#xD;
&#xD;
          -  No ongoing or active infection&#xD;
&#xD;
          -  No prior allergic reaction attributed to compounds of similar chemical or biologic&#xD;
             composition to imatinib mesylate&#xD;
&#xD;
          -  No other malignancy within the past 5 years except basal cell skin cancer or carcinoma&#xD;
             in situ of the cervix&#xD;
&#xD;
          -  No psychiatric illness or social situation that would preclude study compliance&#xD;
&#xD;
          -  Not pregnant or nursing&#xD;
&#xD;
          -  Negative pregnancy test&#xD;
&#xD;
          -  Fertile patients must use effective barrier contraception during and for 1 week after&#xD;
             study&#xD;
&#xD;
          -  No concurrent biologic agents&#xD;
&#xD;
          -  No more than 2 prior chemotherapy regimens for metastatic disease&#xD;
&#xD;
               -  Therapy with high-dose regimens or bone marrow transplantation considered 1&#xD;
                  regimen&#xD;
&#xD;
          -  At least 4 weeks since prior chemotherapy (6 weeks for carmustine or mitomycin) and&#xD;
             recovered&#xD;
&#xD;
          -  No concurrent chemotherapy&#xD;
&#xD;
          -  Prior hormonal therapy for stage IV disease and/or as adjuvant therapy allowed&#xD;
&#xD;
          -  At least 4 weeks since prior radiotherapy and recovered&#xD;
&#xD;
          -  Prior localized radiotherapy that does not influence the signal of the evaluable&#xD;
             lesion is allowed&#xD;
&#xD;
          -  At least 2 weeks since prior minor surgery&#xD;
&#xD;
          -  At least 4 weeks since prior major surgery&#xD;
&#xD;
          -  Recovered from prior surgery&#xD;
&#xD;
          -  Low-molecular weight heparin or heparin allowed for anticoagulation&#xD;
&#xD;
          -  No concurrent warfarin&#xD;
&#xD;
          -  No concurrent combination antiretroviral therapy for HIV-positive patients&#xD;
&#xD;
          -  No concurrent investigational therapies or agents&#xD;
&#xD;
          -  No other concurrent anticancer therapy&#xD;
&#xD;
          -  No concurrent intake of cola, orange juice, grapefruit, or orange or grapefruit&#xD;
             sections&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Massimo Cristofanilli</last_name>
    <role>Principal Investigator</role>
    <affiliation>M.D. Anderson Cancer Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>M D Anderson Cancer Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2013</verification_date>
  <study_first_submitted>September 6, 2002</study_first_submitted>
  <study_first_submitted_qc>January 26, 2003</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 27, 2003</study_first_posted>
  <last_update_submitted>January 22, 2013</last_update_submitted>
  <last_update_submitted_qc>January 22, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 23, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
    <mesh_term>Breast Neoplasms, Male</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Imatinib Mesylate</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

